Compositions of unconjugated estrogens and methods for their use

• US 20060183724A1
• Filed: 02/03/2006
• Published: 08/17/2006
• Est. Priority Date: 02/03/2005
• Status: Abandoned Application

• Current Assignee: Duramed Pharmaceuticals Incorporated
• Original Assignee: Duramed Pharmaceuticals Incorporated
• Inventors: Mahashabde, Anu, Diliberti, Charles E.
• Application Number:
  US11/346,232
• Publication Number:
  US 20060183724A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/566 having an oxo group in position 17, e.g. estrone
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0036 Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
• CPC Class Codes: A61P 15/12 for climacteric disorders

Abstract

The present invention relates to compositions containing unconjugated estrogens and methods of their use in the treatment of conditions associated with hypoestrogenism or reduced estrogen levels in females.

Claims

1. An unconjugated estrogen composition comprising two or more unconjugated estrogens wherein at least one unconjugated estrogen is selected from the group consisting of unconjugated equilin, unconjugated 17α

-dihydroequilin, unconjugated 17β

-dihydroequilin, and combinations thereof, and wherein the unconjugated estrogen composition is substantially free of conjugated estrogens.

2. The unconjugated estrogen composition of claim 1, wherein the composition comprises unconjugated equilin.

3. The unconjugated estrogen composition of claim 1, further comprising an unconjugated estrogen selected from the group consisting of unconjugated 17α

-estradiol, unconjugated Δ

^8,9-dehydroestrone, unconjugated 17β

-estradiol, unconjugated estrone, unconjugated equilenin, unconjugated 17α

-dihydroequilenin, unconjugated 17β

-dihydroequilenin and combinations thereof.

4. The unconjugated estrogen composition of claim 3, wherein the composition comprises unconjugated equilin and unconjugated estrone.

5. The unconjugated estrogen composition of claim 3, wherein the composition comprises unconjugated equilin, unconjugated 17α

-dihydroequilin, unconjugated 17β

-dihydroequilin, unconjugated 17α

-estradiol, unconjugated equilenin, unconjugated 17α

-dihydroequilenin, unconjugated 17β

-dihydroequilenin, unconjugated 17β

-estradiol and unconjugated estrone.

6. The unconjugated estrogen composition of claim 1, wherein the composition is in an anal suppository, buccal, parenteral, transdermal, vaginal, nasal, topical, implantable, or subcutaneous dosage form.

7. The unconjugated estrogen composition of claim 6, wherein the dosage form has a rate of release of about 0.01 μ

g/day to about 2000 μ

g/day of the unconjugated estrogen.

8. The unconjugated estrogen composition of claim 6, wherein the composition is in a vaginal dosage form.

9. The unconjugated estrogen composition of claim 8, wherein the vaginal dosage form is a vaginal ring.

10. The unconjugated estrogen composition of claim 9, wherein the vaginal ring has a rate of release of about 5 μ

g/day to about 200 μ

g/day of the unconjugated estrogen.

11. The unconjugated estrogen composition of claim 9, wherein the vaginal ring comprises a polymer core containing the unconjugated estrogen composition and a polymer sheath that surrounds the polymer core.

12. A method of treating a peri-menopausal or menopausal condition in a female in need thereof, the method comprising administering the composition of claim 9, wherein the vaginal ring releases the unconjugated estrogen at a rate of about 5 μ

g/day to about 200 μ

g/day, and wherein the vaginal ring is administered to the female for a period of about 30 days to about 90 days.

13. The method of claim 12, wherein the peri-menopausal or menopausal condition is selected from the group consisting of vaginal dryness, vaginal atrophy, vulvar atrophy, atrophic vaginitis, vaginal pruritus, dyspareunia, and dysuria.

14. The method of claim 13, wherein the peri-menopausal or menopausal condition is vaginal atrophy.

15. A method of treating a condition resulting from hypoestrogenism in a female in need thereof, the method comprising administering to the female a therapeutically effective amount of the unconjugated estrogen composition of claim 1.

16. The method of claim 15, wherein the condition resulting from hypoestrogenism is a peri-menopausal or menopausal condition.

17. The method of claim 16, wherein the peri-menopausal or menopausal condition is selected from the group consisting of vaginal dryness, vaginal atrophy, vulvar atrophy, atrophic vaginitis, vaginal pruritus, dyspareunia, and dysuria.

18. The method of claim 17, wherein the peri-menopausal or menopausal condition is vaginal atrophy.

19. A method of delivering the unconjugated estrogen composition of claim 1 to a patient in need thereof, the method comprising:

(a) registering the patient in a computer readable storage medium, and

(b) permitting the patient access to the unconjugated estrogen composition.

20. The method of claim 19, wherein the access to the unconjugated estrogen composition is through a prescription.